Neurology 2015: Leading-edge neurology for the practising clinician


A
fter a positive response when it was introduced last year, Neurology 2015 ran for a second year, aiming to present cutting-edge neurology for the modern clinician. The National Hospital for Neurology and Neurosurgery (NHNN) has historically played a major role in guiding practice in the field. With changes in modern medical practice and evidence-based medicine, this institution continues to be involved in guiding modern practice for the management of neurological disorders. This was exemplified by the high quality of talks provided by leaders in the field, who are currently working at the NHNN.

The course presented an ambitious programme of talks centred around six topics in the field, over two days. It kicked off with clinical sessions relating to leading treatments of acute neurological disorders: starting with a comprehensive talk on the clinical manifestations and treatment of Guillain-Barré Syndrome presented by Dr Howard. He discussed new potential treatments, based on recent understandings of the pathophysiology of the condition. This was followed by a talk on treatment of meningitis by Dr Farmer. He discussed the most common pathogens for the disease, options of antibiotic regimes as well as prospects of vaccination. Professor Shorvon discussed the challenging management of super-refractory status epilepticus with an invitation for all participants to register new cases online for the status epilepticus with an invitation for all participants to register new cases online for the disease, options for the management of neurological disorders. This was exemplified by the high quality of talks provided by leaders in the field, who are currently working at the NHNN.

The course presented an ambitious programme of talks centred around six topics in the field, over two days. It kicked off with clinical sessions relating to leading treatments of acute neurological disorders: starting with a comprehensive talk on the clinical manifestations and treatment of Guillain-Barré Syndrome presented by Dr Howard. He discussed new potential treatments, based on recent understandings of the pathophysiology of the condition. This was followed by a talk on treatment of meningitis by Dr Farmer. He discussed the most common pathogens for the disease, options of antibiotic regimes as well as prospects of vaccination. Professor Shorvon discussed the challenging management of super-refractory status epilepticus with an invitation for all participants to register new cases online for the status epilepticus with an invitation for all participants to register new cases online for the disease, options for the management of neurological disorders. This was exemplified by the high quality of talks provided by leaders in the field, who are currently working at the NHNN.

The course presented an ambitious programme of talks centred around six topics in the field, over two days. It kicked off with clinical sessions relating to leading treatments of acute neurological disorders: starting with a comprehensive talk on the clinical manifestations and treatment of Guillain-Barré Syndrome presented by Dr Howard. He discussed new potential treatments, based on recent understandings of the pathophysiology of the condition. This was followed by a talk on treatment of meningitis by Dr Farmer. He discussed the most common pathogens for the disease, options of antibiotic regimes as well as prospects of vaccination. Professor Shorvon discussed the challenging management of super-refractory status epilepticus with an invitation for all participants to register new cases online for the status epilepticus with an invitation for all participants to register new cases online for the disease, options for the management of neurological disorders. This was exemplified by the high quality of talks provided by leaders in the field, who are currently working at the NHNN.

The course presented an ambitious programme of talks centred around six topics in the field, over two days. It kicked off with clinical sessions relating to leading treatments of acute neurological disorders: starting with a comprehensive talk on the clinical manifestations and treatment of Guillain-Barré Syndrome presented by Dr Howard. He discussed new potential treatments, based on recent understandings of the pathophysiology of the condition. This was followed by a talk on treatment of meningitis by Dr Farmer. He discussed the most common pathogens for the disease, options of antibiotic regimes as well as prospects of vaccination. Professor Shorvon discussed the challenging management of super-refractory status epilepticus with an invitation for all participants to register new cases online for the status epilepticus with an invitation for all participants to register new cases online for the disease, options for the management of neurological disorders. This was exemplified by the high quality of talks provided by leaders in the field, who are currently working at the NHNN.

The course presented an ambitious programme of talks centred around six topics in the field, over two days. It kicked off with clinical sessions relating to leading treatments of acute neurological disorders: starting with a comprehensive talk on the clinical manifestations and treatment of Guillain-Barré Syndrome presented by Dr Howard. He discussed new potential treatments, based on recent understandings of the pathophysiology of the condition. This was followed by a talk on treatment of meningitis by Dr Farmer. He discussed the most common pathogens for the disease, options of antibiotic regimes as well as prospects of vaccination. Professor Shorvon discussed the challenging management of super-refractory status epilepticus with an invitation for all participants to register new cases online for the status epilepticus with an invitation for all participants to register new cases online for the disease, options for the management of neurological disorders. This was exemplified by the high quality of talks provided by leaders in the field, who are currently working at the NHNN.